Explore the words cloud of the VSV-EBOPLUS project. It provides you a very rough idea of what is the project "VSV-EBOPLUS" about.
The following table provides information about the project.
SCLAVO VACCINES ASSOCIATION
|Coordinator Country||Italy [IT]|
|Total cost||15˙430˙660 €|
|EC max contribution||8˙553˙750 € (55%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2016-04-01 to 2021-03-31|
Take a look of project's partnership.
|1||SCLAVO VACCINES ASSOCIATION||IT (SIENA)||coordinator||1˙625˙000.00|
|2||GOETEBORGS UNIVERSITET||SE (GOETEBORG)||participant||1˙698˙750.00|
|3||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||1˙696˙875.00|
|4||UNIVERSITA DEGLI STUDI DI SIENA||IT (SIENA)||participant||1˙645˙000.00|
|5||Centre de Recherches Medicales de Lambaréné||GA (Lambaréné)||participant||701˙250.00|
|6||MICROBIOTEC SRL||IT (MONTERIGGIONI)||participant||485˙000.00|
|7||EBERHARD KARLS UNIVERSITAET TUEBINGEN||DE (TUEBINGEN)||participant||395˙625.00|
|8||UNIVERSIDADE DE SAO PAULO||BR (SAO PAULO SP)||participant||306˙250.00|
|9||EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT||CH (BERN)||participant||0.00|
|10||MERCK SHARP & DOHME CORP||US (WHITEHOUSE STATION NJ)||participant||0.00|
|11||UNIVERSITE DE GENEVE||CH (GENEVE)||participant||0.00|
The vesicular stomatitis virus (VSV)-Zaire Ebola vaccine (VSV-ZEBOV) is a recombinant vector-based vaccine in which the VSV envelope glycoprotein was replaced with the Zaire strain Ebola virus glycoprotein. Within one year of the initiation of its clinical development, the VSV-ZEBOV vaccine has demonstrated safety, immunogenicity and a remarkably high protective efficacy against Ebola Virus Disease, using a high vaccine dose (2x107 pfu) in the WHO-sponsored VSV-ZEBOV ring-vaccination trial in adults in Guinea. However, several key questions remain unanswered, including its mode of action, its correlation with protection and reactogenicity, the expected duration of protective efficacy and determinants of long-term responses, the influence of baseline immunity on vaccine “take”, and the vaccine efficacy in children - a most vulnerable population. Following the interruption of the 2014-2015 Ebola Virus Disease (EVD) outbreak, these questions, being central to the future licensing and use of VSV-ZEBOV, may not be addressed by collecting field data. The VSV-EBOPLUS project therefore proposes to use cutting-edge systems biology approaches to address these key questions, capitalizing on the unique availability of large series of extremely well defined samples from clinical vaccine studies with the VSV-ZEBOV vaccine in three different continents (Europe, Africa, US).
Specifically, the overarching objective of VSV-EBOPLUS is to comprehensively decipher the immune and molecular signatures of adult and pediatric responses elicited by VSV-ZEBOV through systems biology approaches. VSV-EBOPLUS will benefit from harmonized and standardized clinical trial protocols, in almost 1’000 adults, adolescents and children. We propose: 1) to examine early (days 0 to 7) blood samples from 512 adults injected with graded doses (from 3x103 to 1x108 pfu) of VSV-ZEBOVÍ¾
|Distribution of samples (serum, plasma, Paxgene tubes) to partners involved in immunogenicity / transcriptomic studies||Documents, reports||2019-10-07 17:33:12|
Take a look to the deliverables list in detail: detailed list of VSV-EBOPLUS deliverables.
|year||authors and title||journal||last update|
Angela Huttner, Claire-Anne Siegrist
Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
published pages: 1105-1110, ISSN: 1476-0584, DOI: 10.1080/14760584.2018.1546582
|Expert Review of Vaccines 17/12||2019-10-07|
Donata Medaglini, Francesco Santoro, Claire-Anne Siegrist
Correlates of vaccine-induced protective immunity against Ebola virus disease
published pages: , ISSN: 1044-5323, DOI: 10.1016/j.smim.2018.07.003
|Seminars in Immunology||2019-10-07|
Angela Huttner, Selidji Todagbe Agnandji, Christophe Combescure, JosÃ© F Fernandes, Emmanuel Bache Bache, Lumeka Kabwende, Francis Maina Ndungu, Jessica Brosnahan, Thomas P Monath, Barbara LemaÃ®tre, StÃ©phane Grillet, Miriam Botto, Olivier Engler, Jasmine Portmann, Denise Siegrist, Philip Bejon, Peter Silvera, Peter Kremsner, Claire-Anne Siegrist, Sanjeev KRISHNA, Marylyn M. ADDO, Stephan BECKER, Verena KRÃ„HLING, Patricia NJUGUNA, Marie-Paule KIENY, Rafi AHMED, Jenna ANDERSON, Floriane AUDERSET, Luisa BORGIANNI, Annalisa CIABATTINI, Marielle C. HAKS, Ali HARANDI, Donald Gray HEPPNER, Alice GERLINI, Donata MEDAGLINI, Tom H.M. OTTENHOFF, David PEJOSKI, Mark PAGE, Gianni POZZI, Francesco SANTORO, Sheri DUBEY, JosÃ© F. FERNANDES, Helder NAKAYA, Fiona OROURKE, Gianni POZZI, Sylvia ROTHENBERGER
Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
published pages: 738-748, ISSN: 1473-3099, DOI: 10.1016/S1473-3099(18)30165-8
|The Lancet Infectious Diseases 18/7||2019-10-07|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VSV-EBOPLUS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VSV-EBOPLUS" are provided by the European Opendata Portal: CORDIS opendata.